President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...

Health care stocks sank after the White House released letters asking big pharmaceutical companies to cut prices and make other changes in the next 60 days. Eli Lilly & Co. fell 2.6%, UnitedHealth ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

On July 31, the Trump administration told 17 major drugmakers to align U.S. medication prices with the lowest prices sold in other countries, or the most-favored-nation price.  The White House ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

The Health Resources and Services Administration has opened applications for a voluntary pilot program aimed at evaluating the 340B rebate model.  The 340B Program traditionally has offered up-front ...